Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non ...

The broker described Neuren as a standout in the ASX biotech sector. The post Macquarie initiates coverage of Neuren ...

BofA Securities analysts on Wednesday lifted ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s price target to $23 from $18, while ...

Across the recent three months, 11 analysts have shared their insights on ACADIA Pharmaceuticals ACAD, expressing a variety ...

Ultimately, Stoke Therapeutics is that classic “intriguing biotech” --hurdling to one of those proverbial “moments of truth” ...

Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, ...

Acadia Pharmaceuticals has scored a second court win in less than a month that protects patents for its Parkinson's Disease treatment Nuplazid. The biopharmaceutical company said Monday that a federal ...

ACADIA Pharmaceuticals (NASDAQ:ACAD) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed ...